Premium
The value of 68 Gallium‐DOTATATE PET / CT in sinonasal neuroendocrine tumor management: A case series
Author(s) -
Liu Katherine Y.,
Goldrich David Y.,
Ninan Sen J.,
Filimonov Andrey,
Lam Hansen,
Govindaraj Satish,
Iloreta Alfred Marc
Publication year - 2021
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.26695
Subject(s) - esthesioneuroblastoma , neuroendocrine tumors , medicine , nuclear medicine , neuroendocrine tumour , somatostatin receptor , neuroendocrine carcinoma , radiology , somatostatin , carcinoma , radiation therapy
Background 68 Gallium‐DOTATATE ( 68 Ga‐DOTATATE) is a somatostatin analog used as a PET tracer to successfully identify neuroendocrine tumors (NETs). Due to the rarity of sinonasal NETs, there are few recommendations for 68 Ga‐DOTATATE imaging in these patients. Methods We discussed the impact of 68 Ga‐DOTATATE imaging on the management of six sinonasal NET cases and reviewed existing literature. Results 68 Ga‐DOTATATE PET/CT revealed an unknown primary in one case and identified metastatic disease in a primary sinonasal small cell neuroendocrine carcinoma (SNEC) patient missed on conventional imaging. In two esthesioneuroblastoma (ENB) patients, 68 Ga‐DOTATATE detected abnormal radiotracer uptake not present on 18F‐FDG PET/CT and identified a patient for treatment with 177 Lu‐DOTATATE. Conclusions This is the one of the first few reports, and the largest series to our knowledge, demonstrating the utility of 68 Ga‐DOTATATE imaging for primary sinonasal SNEC and ENB. Further study is required to determine its role in sinonasal NET management.